References
- Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355:2185–8
- Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85: 1137–42
- Mundy G, Garrett R, Han-is S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946–9
- Maritz FJ, Conradie MM, Hulley PA, et al. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21:1636–41
- Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15:275–300
- Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;2:1151–54
- The Writing Group for the PEPI. Effects of hor-mone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 1996;276:1389–96
- Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141–6
- Eaker ED, Chesebro JH, Sacks FM, et al. Cardio-vascular disease in women. Circulation 1993;88: 1999–2009
- Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham study. In Eaker E, Packard B, Wenger NK, et al., eds. Coronary Heart Disease in Women. New York: Haymarket Doyma, 1987:122–32
- van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. J Am Med Assoc 2001; 285:1850–5
- Sirola J, Sirola J, Honkanen R, et al. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 2002;13:537–41
- Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581–9
- Funkhouser HL, Adera T, Adler RA. Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density.J Clin Densitom 2002;5:151–8
- Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002;162: 537–40
- Chan MH, Mak TW, Chiu RW, et al. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 2001;86:4556–9